title: Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial.
abstract: OBJECTIVE
  To test the modulation of farnesoid X receptor activity on the replication of hepatitis C virus in chronically infected patients.
  
  
  METHODS
  This is a proof-of-concept trial that was approved by the ex-French Agency for the Safety of Health Products (ex-Afssaps [currently ANSM]) and an ethics committee. It has started in January 2010. This one-arm, open-label study examines the safety and efficacy of the oral administration of guggulsterone. The main outcome measure will be the assessment of blood viral loads.
  
  
  RESULTS
  We planned to enrol 15 genotype 1-infected patients that failed a first-line therapy.
  
  
  CONCLUSIONS
  We think guggulsterone might be an effective therapeutic option for HCV genotype 1 patients who do not respond well to first-line therapy.
authors.affiliation: Hospices Civils de Lyon, Hôpital de la Croix Rousse, Laboratory of Virology, Lyon, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Scholtes
authors.forename: Patrice
authors.initials: P
authors.lastname: André
authors.forename: Christian
authors.initials: C
authors.lastname: Trépo
authors.forename: Catherine
authors.initials: C
authors.lastname: Cornu
authors.forename: Laurent
authors.initials: L
authors.lastname: Remontet
authors.forename: René
authors.initials: R
authors.lastname: Ecochard
authors.forename: Theodora
authors.initials: T
authors.lastname: Bejan-Angoulvant
authors.forename: François
authors.initials: F
authors.lastname: Gueyffier
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002985:Clinical Protocols; D055317:Evidence-Based Practice; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D010865:Pilot Projects; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors*; D016879:Salvage Therapy; D019562:Viral Load / Q000187:drug effects; D055815:Young Adult; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D000998:Antiviral Agents; D011282:Pregnenediones; D018160:Receptors, Cytoplasmic and Nuclear; D000099150:Receptor, Farnesoid X-Activated; C023617:pregna-4,17-diene-3,16-dione